Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials

Researchers in the Duke Division of Pulmonary, Allergy, and Critical Care Medicine are actively engaged in clinical trials that examine effective treatment options for chronic obstructive pulmonary disease (COPD).

Current Clinical Trials

The following clinical research initiatives are being conducted in our division:

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (OBERON).

The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subjcutaneously (SC) in adults with symptomatic COPD and a history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Potential participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA) in stable doses throughout at least 3 months prior to enrolment.

Principal Investigator: Loretta Que, MD
Status: Pending Recruitment
IRB Number: Pro00110508
Clinical #: NCT05166889
Study Team Contact: Jessica Shier –


A Multi-center, Randomized, 36-month, Parallelgroup, Non-inferiority, Phase III Study to Compare the Effectiveness of 500 mcg QD or alternate regimen of RofLumilast (Daliresp) Therapy Versus 250 mg QD, 500 mg QD three times per week or alternate regimen of Azithromycin Therapy to preveNt COPD Exacerbations (RELIANCE)

Principal Investigator: Christopher Mosher, MD
Status: Recruiting
IRB Number: Pro0010046
Clinical #: NCT04069312
Study Team Contact: Jessica Shier –


This study will test whether daily use of azithromycin will reduce the rate of exacerbations and improve lung ventilation and perfusion assessed by XE-MRI. The sensitivity of XE-MRI to detect COPD progression will be compared with standard clinical assessment measures including standard lung function testing, 6 minute walk testing, and patient reported qualify of life.

Principal Investigator: Tony Huang, MD
Status: Recruiting
IRB Number: Pro00105201
Clinical #: NCT04353661
Study Team Contact: Katie Williford -

Enroll in a Pulmonary Clinical Trial at Duke

Researchers in our division are investigating a variety of treatments and therapies to respond to lung disease.
Click here  to view a list of current clinical trials for Pulmonary.